nature.com
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Nature - In a phase I/II dose-escalation clinical trial, the mRNA COVID-19 vaccine BNT162b1 elicits specific T cell and antibody responses that suggest it has protective potential.